Lecanemab drug

About:

• Lecanemab, is jointly developed by pharma companies Biogen and Eisai.
• Lecanemab belongs to a class of drugs called monoclonal antibodies. These antibody-mediated drugs target beta amyloid, the protein deposition that is seen in patients with Alzheimer’s disease, and disrupts cells function.

Alzheimer’s disease

• It is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die.  It involves parts of the brain that control thought, memory, and language.
• It can seriously affect a person’s ability to carry out daily activities.

India’s scenario:

• In India, only 1 in 10 peoplewith dementia receive any diagnosis, treatment or care for the disease, according to the World Alzheimer’s Report, 2021.